EQ · Equillium, Inc.
$2.28
-0.04 (-1.72%)
At close · Jul 29
Market Cap
$146.69M
Shares
63.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.28
Open$2.27
Day$2.18–2.36
52W$0.37–3.54
Avg vol 30d816K
Short int5.6M · 8.8% float · 4.5d
Short vol52%
Last earningsMay 27, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Apr 1, 2027
Est · unconfirmed
· in 35 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
−16%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
60%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−29%
trailing
6-month return
+51%
trailing
YTD return
+47%
this year
Relative strength
+45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
4 of 50 funds reported for Jun 30 · net +58.4K sh shares · +2 new
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Rising
8.81% of float · ▲ +8.9% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
50 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+14%
Y/Y
EPS growth
−70%
Y/Y
Free cash flow
$-22.8M
Balance sheet
$21.3M
net cash
Quant / Vol
risk profile
Volatility
164%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
10.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
−16%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
60%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
4 of 50 funds reported for Jun 30 · net +58.4K sh shares · +2 new
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Rising
8.81% of float · ▲ +8.9% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
50 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $2 · 60%
52-wk high $4
vs 200-day avg +23%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EQ
this stock
Equillium, Inc.
|
$146.69M | +47.1% | +13.9% | — | 8.8% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EQ | -17.4% | -28.8% | +51.0% | -28.8% | +47.1% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -15.0% | -26.4% | +44.7% | -26.4% | +40.1% |